Vascular obstruction retrieval device having sliding cages pinch mechanism

Information

  • Patent Grant
  • 12064130
  • Patent Number
    12,064,130
  • Date Filed
    Thursday, March 18, 2021
    3 years ago
  • Date Issued
    Tuesday, August 20, 2024
    3 months ago
Abstract
The disclosed technology includes a clot retrieval device being configured to retrieve a clot from a blood vessel and having a constrained delivery configuration and a clot engaging configuration. The device can include a first expandable framework having a first plurality of struts that form a first body and a second expandable framework having a second plurality of struts that form a second body upon the clot retrieval device transitioning from the constrained delivery configuration to the clot engaging configuration. In the clot engaging configuration, the first body can be configured to move from a first position to a second position in relation to the second body. Upon moving from the first position to the second position, the clot retrieval device can pinch the clot between the first body and the second body.
Description
FIELD OF INVENTION

The present disclosure relates generally to devices and methods for removing blockages from blood vessels during intravascular medical treatments.


BACKGROUND

Clot retrieval devices are used in mechanical thrombectomy for endovascular intervention, often in cases where patients are suffering from conditions such as acute ischemic stroke (AIS), myocardial infarction (MI), and pulmonary embolism (PE). Acute obstructions can include a clot, misplaced devices, migrated devices, large emboli, and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow. An ischemic stroke can result if the clot lodges in the cerebral vasculature. A pulmonary embolism can result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots can also develop and block vessels locally without being released in the form of an embolus—this mechanism is common in the formation of coronary blockages.


There are significant challenges associated with designing clot retrieval devices that can deliver high levels of performance. First, there are a number of access challenges that make it difficult to deliver devices. In cases where access involves navigating the aortic arch (such as coronary or cerebral blockages) the configuration of the arch in some patients makes it difficult to position a guide catheter. These difficult arch configurations are classified as either type 2 or type 3 aortic arches with type 3 arches presenting the most difficulty.


The tortuosity challenge is even more severe in the arteries approaching the brain. For example, it is not unusual at the distal end of the internal carotid artery that the device will have to navigate a vessel segment with a 180° bend, a 90° bend, and a 360° bend in quick succession over a few centimeters of vessel. In the case of pulmonary embolisms, access is through the venous system and then through the right atrium and ventricle of the heart. The right ventricular outflow tract and pulmonary arteries are delicate vessels that can easily be damaged by inflexible or high profile devices. For these reasons it is desirable that the clot retrieval device be compatible with as low profile and flexible a guide catheter as possible.


Second, the vasculature in the area in which the clot can be lodged is often fragile and delicate. For example, neurovascular vessels can be more fragile than similarly sized vessels in other parts of the body and can be in a soft tissue bed. Excessive tensile forces applied on these vessels could result in perforations and hemorrhage. Pulmonary vessels can be larger than those of the cerebral vasculature, but are also delicate in nature, particularly more distal vessels.


Additionally, the clot can have any of a range of morphologies and consistencies. For example, the clot can be difficult to grip and improper grip can lead to fragmentation which can cause embolization. Long strands of softer clot material can also tend to lodge at bifurcations or trifurcations, resulting in multiple vessels being simultaneously occluded over significant lengths. More mature and organized clot material can be less compressible than softer fresher clot, and under the action of blood pressure it can distend the compliant vessel in which it is lodged. Furthermore, the properties of the clot can be significantly changed by the action of the devices interacting with it. In particular, compression of a blood clot can cause dehydration of the clot and can result in a dramatic increase in both clot stiffness and coefficient of friction.


Lastly, traditional clot retrieval devices employing a pinch mechanism to capture a clot can require the delivery microcatheter to be forward post deployment of the clot retrieval device in order to effectively pinch a clot using the device. However, this can add an additional step in the procedure, thereby resulting in a potentially cumbersome and non-optimal procedure. Due to the critical nature of such procedures, it can be critical to capture a clot in a timely and effective manner.


The challenges described above need to be overcome for devices to provide a high level of success in removing clot and restoring flow.


SUMMARY

It is desirable for a clot retrieval device to remove a clot from cerebral arteries in patient suffering from AIS, from coronary native or graft vessels in patients suffering from MI, and from pulmonary arteries in patients from PE and from other peripheral arterial and venous vessels in which a clot is causing at least a partial occlusion. Example devices and methods presented herein may be suitable for at least some of such procedures and/or similar procedures.


An example clot retrieval device can have a constrained delivery configuration and a clot engaging configuration and can be configured to remove a clot from a blood vessel. The device can include a first expandable framework having a first plurality of struts that form a first body and a second expandable framework having a second plurality of struts that form a second body. In the clot engaging configuration, the first body can be configured to move from a first position to a second position in relation to the second body.


The first body can have a first inner diameter and the second body can have a second inner diameter. The first inner diameter and the second inner diameter can be substantially equal.


When the first body is in the first position, the first plurality of struts and the second plurality of struts can be disengaged such that a plurality of clot reception spaces are formed.


When the first body is in the second position, the first plurality of struts and the second plurality of struts can be engaged such that an average cross-sectional area of the plurality of clot reception spaces decreases upon movement of the first body from the first position to the second position.


The first plurality of struts can include a radially extending strut and the second plurality of struts can include an eye through which the radially extending strut radially extends. The eyelet and the radially extending strut can be configured such that when the first body moves from the first position to the second position, the radially extending strut engages the eyelet to inhibit the first plurality of struts from moving, in relation to the second plurality of struts, beyond the second position. Each eyelet can be tapered.


The clot retrieval device can include a polymer coating to engage the first plurality of struts and the second plurality of struts. The polymer coating can be configured to fail, thereby allowing the first body to move from the first position to the second position.


At least one polymer membrane can be affixed to the first plurality of struts and the second plurality of struts such that the polymer membrane is disposed between the first body and the second body.


The at least one polymer membrane can be in a folded configuration when the first body is in the first position and the at least one polymer membrane can transition to a stretched configuration when the first body moves proximally to the second position.


The clot retrieval device can include a third expandable framework having a third framework of struts that form a third body. The first body and the second body can at least partially surround the third body in the clot engaging configuration.


A proximal end of the clot retrieval device can include a plurality of expanded struts that form a collar.


The third framework of struts can include at least one disconnected strut.


The third body can include a plurality of clot reception spaces. The plurality of clot reception spaces can be configured to engage the clot.


Another example clot retrieval device can have a constrained delivery configuration and a clot engaging configuration and can be configured to remove a clot from a blood vessel. The device can include an inner expandable framework, an outer expandable framework, and a spring. The inner expandable framework can be affixed to a pull wire and can include a first plurality of struts that form an inner body. The outer expandable framework can be affixed to the pull wire and can include a second plurality of struts that form an outer body at least partially surrounding the inner body. The spring can be affixed to a distal end of the pull wire and can have a compressed configuration and an elongated configuration. In the clot engaging configuration, the inner body can be configured to move from a first position to a second position in relation to the outer body such that the spring transitions from the compressed configuration to the elongated configuration.


The outer expandable framework can include a plurality of clot reception spaces that are configured to pinch the clot between the inner body and the outer body when the inner body moves from the first position to the second position.


An example method to capture a clot can include deploying a clot retrieval device proximate the clot where the clot retrieval device includes a first expandable framework forming a first body and a second expandable framework forming a second body at least partially surrounding the first body. The method can further include moving the first body in relation to the second body to pinch at least a portion of the clot between the first body and the second body and capturing one or more fragments of the clot.


Moving the first body in relation to the second body to pinch at least a portion of the clot between the first body and the second body can include applying tension to a pull wire where the pull wire is in mechanical communication with the first body.


The method can further include retracting the first body and the second body simultaneously.


The clot retrieval device can further include a third expandable framework having a third plurality of struts that form a third body. The first body and the second body can at least partially surround the third body. In such configuration, the method can further include retracting the third body in a proximal direction to engage the first body and the third body.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a side view of an example clot retrieval device in a clot engaging configuration, in accordance with the present disclosure.



FIG. 1B is an additional side view from a different perspective of the clot retrieval device of FIG. 1A, in accordance with the present disclosure.



FIG. 1C is a cross-section view of a shaft of the clot retrieval device of FIGS. 1A and 1B, in accordance with the present disclosure.



FIG. 1D is an expanded view of the pull wire joined to a first plurality of struts of the clot retrieval device of FIGS. 1A and 1B, in accordance with the present disclosure.



FIG. 1E is an expanded view of a radially extending strut and an eyelet of the clot retrieval device of FIGS. 1A and 1B, in accordance with the present disclosure.



FIG. 1F is a side view of the clot retrieval device of FIGS. 1A and 1B upon transitioning to a clot pinching configuration, in accordance with the present disclosure.



FIG. 1G is an additional side view of the clot retrieval device in the clot pinching configuration illustrated in FIG. 1F, in accordance with the present disclosure.



FIG. 2A is a side view of an additional example clot retrieval device in a clot engaging configuration, in accordance with the present disclosure.



FIG. 2B is a cross-sectional view of a proximal portion of the clot retrieval device of FIG. 2A, in accordance with the present disclosure.



FIGS. 2C-2E illustrate examples of a third body of the clot removal device of FIG. 2A, in accordance with the present disclosure.



FIG. 2F is an additional side view of the clot retrieval device of FIG. 2A, in accordance with the present disclosure.



FIG. 2G illustrates an example third collar of the clot removal device of FIG. 2A, in accordance with the present disclosure.



FIG. 3A illustrates an additional example clot retrieval device having a spring in a compressed configuration, in accordance with the present disclosure.



FIG. 3B illustrates the clot retrieval device of FIG. 3A where the spring is in an elongated configuration, in accordance with the present disclosure.



FIG. 4 is a flow diagram outlining a method of capturing a clot using the clot retrieval device of FIGS. 1A through 1G.



FIG. 5 is a flow diagram outlining a method of capturing a clot using the clot retrieval device of FIGS. 2A through 2G.





DETAILED DESCRIPTION

The design and functionality described in this application is intended to be exemplary in nature and is not intended to limit the instant disclosure in any way. Those having skill in the pertinent art will appreciate that the teachings of the disclosure may be implemented in a variety of suitable forms, including those forms disclosed herein and additional forms known to those having skill in the art pertinent.


It will be apparent from the foregoing description that, while particular embodiments of the present disclosure have been illustrated and described, various modifications can be made without departing from the spirit and scope of the disclosure. For example, while the embodiments described herein refer to particular features, the disclosure includes embodiments having different combinations of features. The disclosure also includes embodiments that do not include all of the specific features described. Specific embodiments of the present disclosure are now described in detail with reference to the figures, wherein identical reference numbers indicate identical or functionality similar elements.


The terms “distal” or “proximal” are used in the following description with respect to a position or direction relative to the treating physician. “Distal” or “distally” are a position distant from or in a direction away from the physician. “Proximal” or “proximally” or “proximate” are a position near or in a direction toward the physician.


In the following description, numerous specific details are set forth. But it is to be understood that examples of the disclosed technology can be practiced without these specific details. In other instances, well-known methods, structures, and techniques have not been shown in detail in order not to obscure an understanding of this description. References to “one embodiment,” “an embodiment,” “example embodiment,” “some embodiments,” “certain embodiments,” “various embodiments,” “one example,” “an example,” “some examples,” “certain examples,” “various examples,” etc., indicate that the embodiment(s) and/or example(s) of the disclosed technology so described may include a particular feature, structure, or characteristic, but not every embodiment necessarily includes the particular feature, structure, or characteristic. Further, repeated use of the phrase “in one embodiment” or the like does not necessarily refer to the same embodiment, example, or implementation, although it may.


By “comprising” or “containing” or “including” or “having” is meant that at least the named compound, element, particle, configuration, or method step is present in the composition or device or method, but does not exclude the presence of other compounds, materials, particles, method steps, or configurations even if the other such compounds, material, particles, method steps, or configurations have the same function as what is named.


Throughout the specification and the claims, the following terms take at least the meanings explicitly associated herein, unless the context clearly dictates otherwise. The term “or” is intended to mean an inclusive “or.” Further, the terms “a,” “an,” and “the” are intended to mean one or more unless specified otherwise or clear from the context to be directed to a singular form.


Unless otherwise specified, the use of the ordinal adjectives “first,” “second,” “third,” etc., to describe a common object, merely indicate that different instances of like objects are being referred to, and are not intended to imply that the objects so described should be in a given sequence, either temporally, spatially, in ranking, or in any other manner.


As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein. More specifically, “about” or “approximately” may refer to the range of values ±20% of the recited value, e.g. “about 90%” may refer to the range of values from 71% to 99%.


As discussed herein, a “patient” or “subject” can be a human or any animal. It should be appreciated that an animal can be a variety of any applicable type, including, but not limited to, mammal, veterinarian animal, livestock animal or pet-type animal, etc. As an example, the animal can be a laboratory animal specifically selected to have certain characteristics similar to a human (e.g., rat, dog, pig, monkey, or the like).


Accessing the various vessels within the vascular, whether they are coronary, pulmonary, or cerebral, involves well-known procedural steps and the use of a number of conventional, commercially-available accessory products. These products, such as angiographic materials and guidewires are widely used in laboratory and medical procedures. When these products are employed in conjunction with the system and methods of this disclosure in the description below, their function and exact constitution are not described in detail.


The disclosed technology can generally include a clot removal device having a sliding cage (e.g., a first body) and an outer cage (e.g., a second body) radially surrounding the sliding cage. A pull wire can be affixed to the sliding cage such that upon tension being applied to the pull wire, the sliding cage can displace proximally and independently of the outer cage. Upon the sliding cage displacing proximally, the sliding cage and the outer cage can pinch the clot. In some instances, the clot removal device can further include an inner channel (e.g., third body). The outer cage and the sliding cage can radially surround the inner channel. Upon tension being applied, the inner channel can move proximally and independently of the outer cage and sliding cage. Subsequently, the sliding cage can move proximally in relation to the outer cage and independently of the outer cage. In such configuration the sliding cage and the outer cage can further pinch the clot and the clot can thereby become further integrated within the clot removal device. Accordingly, the efficient and effective removal of a clot from a blood vessel can be performed.


Referring now to the Figures, FIGS. 1A and 1B illustrate side views of an example clot retrieval device 100 in a clot engaging configuration. The clot retrieval device 100 can include a first expandable framework 102 and a second expandable framework 104. The first expandable framework 102 can include a first plurality of struts 106 and the second expandable framework 104 can include a second plurality of struts 108.


The first expandable framework 102 and the second expandable framework 104 can be collapsible into a restraining sheath (e.g., a microcatheter) sized to traverse a clot or other obstruction. The clot retrieval device 100 can be positioned proximate the clot in a blood vessel. Optionally, the clot retrieval device 100 can traverse the clot such that a portion of the clot remove device 100 is forward in relation to the clot. The first expandable framework 102 and the second expandable framework 104 can each be configured to self-expand upon release from the restraining sheath. Upon release, the clot retrieval device 100 can transition from a constrained delivery configuration to the clot engaging configuration such that the clot retrieval device 100 can be subsequently used to facilitate clot removal, flow restoration, and or fragmentation protection.


Upon transitioning to the clot engaging configuration, the first plurality of struts 106 of the first expandable framework 102 can expand to form a first body 110. Similarly, the second plurality of struts 108 of the second expandable framework 104 can expand to form a second body 112. The second body 112 can at least partially radially surround the first body 110. Optionally, the second body 112 can entirely radially surround the first body 110.


Both the first expandable framework 102, including the first plurality of struts 106, and the second expandable framework 104, including the second plurality of struts 108, can preferably be made from a material capable of recovering its shape automatically once released from the constrained delivery configuration. A super-elastic or pseudo-elastic material such as Nitinol or an alloy of similar properties is particularly suitable. The material can have a high recoverable strain sufficient to resiliently collapse and expand as described herein. The material could be in many forms such as wire or strip or sheet or tube. A particularly suitable manufacturing process is to laser cut a Nitinol tube and then heat set and electropolish the resultant structure to create a framework of struts and connecting elements. For example, the first expandable framework 102 and the second expandable framework 104 can each be laser cut from a Nitinol tube having an outer diameter of approximately 0.40 millimeters. Each of the cells in the first and second expandable frameworks 102, 104 can be any of a range of shapes as understood by a person skilled in the pertinent art according to the teachings disclosed herein. The first and second expandable frameworks 102, 104 can be rendered visible under fluoroscopy through the addition of alloying elements or through a variety of other coatings or marker bands. For instance, the first and second expandable frameworks 102, 104 can include material and/or markers with radiopaque material including, but not limited to Barium Sulphate, Bismuth SubCarbonate, Barium OxyChloride, Gold, Tungsten, Platinum, Iridium, Tantalum, and alloys thereof. Specifically, in some examples, the first and second expandable frameworks 102, 104 can include radiopaque markers having an Iridium alloy, and more specifically a Platinum-Iridium alloy.


As illustrated in FIGS. 1A and 1B, in the clot engaging configuration, the first body 110 and the second body 112 can each have a substantially cylindrical shape. Further, the first body 110 can have a first inner diameter 134 and the second body 112 can have a second inner diameter 136. The first inner diameter 134 can be approximately the same as the second inner diameter 136 such that the first body 110 and the second body 112 can substantially align with each other. By way of example, the first inner diameter 134 of the first body can be approximately 4.75 millimeters and the second inner diameter 136 can be approximately 5 millimeters. Because the first body 110 and the second body 112 have substantially equal inner diameters 132, 134, the first body 110 can exert an outward force onto the second body 112 in the clot engaging configuration.



FIGS. 1A and 1B illustrate the first body 110 and the second body 112 in a first position. The first plurality of struts 106 can form a first plurality of scaffolding segments 138a having closed cells and the second plurality of struts 108 of the second body 112 can form a second plurality of scaffolding segments 138b also having closed cells. The first plurality of scaffolding segments 138a and the second plurality of scaffolding segments 138b can be substantially aligned with each other. A gap can be formed between each scaffolding segment of the first and second plurality of scaffolding segments 138a, 138b. Such gap can be a clot reception space 120 configured to receive a clot. Portions of the clot can enter such clot reception spaces 120, thereby being captured by the clot retrieval device 100, upon the first body 110 moving from the first position to a second position in relation to the second body 112 as further discussed herein.


A distal end of the first body 110 and the second body 112 can form a distal basket 122. The distal basket 122 can have a substantially conical shape and can mitigate and/or prevent captured fragments of a clot from migrating out of the clot retrieval device 100.


As further illustrated in FIGS. 1C and 1D, a proximal end of the clot retrieval device 100 can include a shaft 132 including a pull wire 114 surrounded by an outer sheath 116. Proximal struts of the first plurality of struts 106 can be affixed to the pull wire 114, as illustrated in FIG. 1D. The pull wire 114 can be made of stainless steel, MP35N, Nitinol, or other material of suitably high modulus and tensile strength. The pull wire 114 can preferably have a solid core but can also have a hollow core. The first plurality of struts 106 of the first body 110 can be affixed to the pull wire 114 at a joint 130 via welding, bonding, by virtue of being cut from a contiguous tube, or other means of attachment. The joint 130 can be created at the approximate location of attachment of the proximal struts of the first plurality of struts 106 and the pull wire 114. Such joint 130 can inhibit unintended movement beyond a desired position when the first body 110 moves in relation to the second body 112 as further discussed herein. The second plurality of struts 108 of the second body 112 can be joined to the outer sheath 116, via welding, bonding, or the second body 112 can be formed using the same Nitinol or other material tubing of the outer sheath 116. Because the first body 110 and the second body 112 are affixed to independent portions of the shaft 132 (e.g., the pull wire 114 and the outer sheath 116, respectively), the first body 110 and the second body 112 can move independently of each other upon tension being applied to the pull wire 114 as further discussed herein.



FIG. 1E illustrates an expanded view of the substantially aligned first body 110 and the second body 112 and including an optional radially extending strut 126 and eyelet 124 to inhibit range of sliding movement between the first body 110 and the second body 112. As illustrated, the second body 112 can radially surround the first body 110 such that the second plurality of struts 108 are exterior to the first plurality of struts 106. The second plurality of struts 108 can further include one or more eyelets 124, and the first plurality of struts 106 can include one or more radially extending “connector” struts each extending through a respective eyelet 124. Each eyelet 124 can have an elongated or alternatively shaped opening. By way of example, the eyelet 124 can be substantially ovular, circular, rectangular, or the like. In some example, the eyelet 124 can be substantially tapered.



FIGS. 1F and 1G illustrate side views of the clot retrieval device 100 in a clot pinching configuration in which the first body 110 moves (e.g., slides) from the first position as illustrated in FIGS. 1A and 1B to a second position in relation to the second body 112. The pull wire 114 can be pulled in the proximal direction to apply tension. The tension can cause the first body 110 to move from the first position (FIGS. 1A and 1B) to the second position (FIGS. 1F and 1G) in relation to the second body 112. Accordingly, the first body 110 can slide from the first position to the second position in relation to the second body 112 such that the first body 110 and the second body 112 become engaged with one another. For example, the first body 110 can slide less than approximately 5 millimeters in relation to the second body 112. Optionally, the first body 110 can slide less than approximately 4 millimeters in relation to the second body 112. Optionally, the first body 110 can slide less than approximately 2 millimeters in relation to the second body 112. Optionally, the first body 110 can slide less than approximately 0.5 millimeters in relation to the second body 112. When the first body 110 moves from the first position to the second position and the device 100 includes one or more radially extending struts 126 through respective eyelets 124 as illustrated in FIG. 1E, the radially extending struts 126 can engage with the eyelets 124, thereby allowing the first body 110 and the second body 112 to become engaged with one another. Further, the eyelet 124 can inhibit the first body 110 from moving, in relation to the second body 112, beyond the second position, as the eyelet 124 can restrict the radially extending strut 126 from moving too far in the proximal direction.


Additionally, or alternatively, the first expandable framework 102 and the second expandable framework 104 can be coated with a polymer coating (e.g., parylene) to temporarily hold the first body 110 in the first position in relation to the second body 112. Upon the pull wire 114 being pulled in the proximal direction, the polymer coating can fail such that the first body 110 can move from the first position to the second position in relation to the second body 112. Aspiration can be applied in order to remove particulate from the failed polymer coating.


Additionally, or alternatively, a shape memory effect of the first body 110 and the second body 112 can be used to cause automatic displacement of the first body 110 after a predetermined time period has lapsed. For example, the second plurality of struts 108 of the second expandable framework 104 can be heat treated locally to increase the austenite finish temperature to a range greater than a typical body temperature during a stroke or other critical body occurrence. The second plurality of struts 108 can expand upon being re-sheathed then be heated to the austenite finish temperature by electrical current. Upon the austenite finish temperature being reached, the first body 110 can automatic move (e.g., slide) in relation to the second body 112 from the first position to the second position, such that the clot can be pinched between the first body 110 and the second body 112.


The pull wire 114 can be pulled in the proximal direction such that the first body 110 moves (e.g., slides) in the proximal direction until the proximal struts of the first plurality of struts 106 encounter the joint 130 positioned proximate the shaft 132. As such, the joint 130 can act as a mechanism to prevent undesired movement beyond the second position. As the first body 110 moves from the first position to the second position the average cross-sectional area of the plurality of clot reception spaces 120 can decrease (e.g., at least partially close). For example, the plurality of clot reception spaces 120 can at least partially close when the first plurality of scaffolding segments 138a slide in relation to the second plurality of scaffolding segments 138b such that the first plurality of scaffolding segment 138a become disposed across the clot reception spaces 120. Thereby, the clot can be pinched between the first body 110 and the second body 112. Pinching of the clot can prevent the clot from migrating out of the clot retrieval device 100, particularly upon retraction of the clot retrieval device 100, as the pinch can increase the grip of the clot retrieval device 100 as compared to other clot retrieval devices, particularly fibrin rich clots. Accordingly, the clot retrieval device 100 can ensure effective and efficient removal of the clot from the patient.


As illustrated in FIGS. 1F and 1G, the clot retrieval device 100 can include a polymer membrane 128 disposed between the first body 110 and the second body 112. The polymer membrane 128 (e.g., elastic membrane) can be configured to transition from a folded configuration when the first body 110 is in the first position such that the first body 110 and the second body 112 are disengaged to a stretched configuration upon the first body 110 moving from the first position to the second position. The polymer membrane 128 can thereby function to limit lateral movement of the first body 110 in relation to the second body 112 in addition to, or as an alternative to the radially extending strut 126 and eyelet 124 illustrated in FIG. 1E. The polymer membrane 128 can be formed by threading microfibers through the eyelets 124 of the second body 112, and/or the polymer membrane 128 can be formed by hooking the polymer membrane 128 into the eyelets 124. The polymer membrane 128 can prevent the clot from migrating out of the clot retrieval device 100 once the clot has been pinched between the first body 110 and the second body 112. Although FIGS. 1F and 1G illustrate the polymer membrane 128 in one location, it is contemplated that the clot retrieval device 100 can include additional polymer membranes 128 over multiple locations. For example, the clot retrieval device 100 can include a first polymer membrane proximate the distal basket of the 122 and a second polymer membrane proximate the shaft 132.



FIG. 2A illustrates an additional example clot retrieval device 200. As discussed above with reference to the clot retrieval device 100 illustrated in FIGS. 1A through 1G, the clot retrieval device 200 can similarly include the first expandable framework 102 including a first plurality of struts 106 and a second expandable framework 104 including a second plurality of struts 108. Upon the clot retrieval device 200 being deployed from a restraining sheath (e.g., microcatheter) and transitioning from a constrained delivery configuration to a clot engaging configuration, the first plurality of struts 106 of the first expandable framework 102 can self-expand to form the first body 110 and the second plurality of struts 108 of the second expandable framework 104 can self-expand to form the second body 112. The first body 110 and the second body 112 can be substantially cylindrical. Additionally, the first body 110 and the second body 112 can have substantially equal inner diameters 134, 136. As such, and as discussed above, the plurality of scaffolding sections 138a, 138b of the first body 110 and the second body 112 can be substantially aligned with one another.


In contrast to the clot retrieval device 100 illustrated in FIGS. 1A through 1G, the clot retrieval device 200 can further include a third expandable framework 202 having a third plurality of struts 204. Upon the clot retrieval device 200 being deployed from the restraining sheath, the third plurality of struts 204 of the third expandable framework 202 can self-expand to form a third body 206. The third body 206 can be substantially porous. Further, the third body 206 can similarly be substantially cylindrical and can have an inner diameter 238 that is less than the inner diameter 134 of the first body 110 and the inner diameter 136 second body 112. Thereby, the first body 110 and the second body 112 can radially surround the third body 206. Optionally, the third body 206 can have an inner diameter 238 that is approximately half (½) the size of the inner diameter 134 of the first body 110 and inner diameter 136 of the second body 112. Optionally, the third body 206 can have an inner diameter 238 that is approximately three quarters (¾) the size of the inner diameter 134 of the first body 110 and the inner diameter 136 of the second body 112. The third expandable framework 202 can be preferably made from a material capable of recovering its shape automatically once released from a constricted delivery configuration. A super-elastic or pseudo-elastic material such as Nitinol or an alloy of similar properties is particularly suitable. The material can have a high recoverable strain sufficient to resiliently collapse and expand as described herein. The material could be in many forms such as wire or strip or sheet or tube. A particularly suitable manufacturing process is to laser cut a Nitinol tube and then heat set and electropolish the resultant structure to create a framework of struts and connecting elements. Optionally, the third expandable framework 202 can be laser cut from a Nitinol tube.


As discussed above with reference to the clot retrieval device 100, the first body 110 can include a first plurality of scaffolding segments 138a and the second body 112 can include a second plurality of scaffolding segments 138b. The first and second plurality of scaffolding segments 138a, 138b can substantially align with one another. A gap can be formed between each scaffolding segment of the first plurality and second plurality of scaffolding segments 138a, 138b. Such gap can be a clot reception space 120 configured to receive at least a portion of a clot upon the clot retrieval device 200 transitioning to a clot pinching configuration as further described herein. The configuration of the third body 206 can similarly create additional clot reception spaces 230 as further discussed herein.


The distal end of the clot retrieval device 200 can include the distal basket 122. The distal basket 122 can have a substantially conical shape and can mitigate captured fragments of a clot from migrating out of the clot retrieval device 200.


As further illustrated in FIG. 2B, a plurality of expanded struts 208a, 208b can be formed from the shaft 216 of the first body 110. For example, the shaft 216 of the first body 110 can be a tube (e.g., Nitinol tube) and the two expanded struts 208a, 208b can be formed (e.g., laser cut) from such tube. The shaft 216 of the first body 110 can be a hollow tube sized to receive the pull wire 114. As such, the pull wire 114 can extend through the shaft 216 of the first body 110. The plurality of expanded struts 208a, 208b can facilitate improved pinching when the clot retrieval device 200 transitions to the clot pinching configuration. Optionally, the plurality of expanded struts 208a, 208b can be used to allow re-expansion of the third body 206 to stabilize the clot if an effective pinch is not formed upon the clot retrieval device 200 transitioning to the clot pinching configuration. A shaft 222 of the second body 112 can surround the shaft 216 of the first body 110 and the pull wire 114. The shaft 222 of the second body 112 can be a tube (e.g., a Nitinol tube). Proximal struts 224 of the second body 112 can extend from a distal end of the shaft 222 of the second body 112. The proximal struts 224 can be the most proximal struts of the second expandable framework 104. A proximal end of a shaft 218 of the third body 206 can be affixed to a distal end of the pull wire 114. The shaft 218 of the third body 206 can be a solid core tube. A joint 220 (e.g. weld joint) can be formed where the shaft 218 of the third body 206 is affixed to the pull wire 114 and where the shaft 216 of the first body 110 forms the expanded struts 208a, 208b. Proximal struts 226 of the third body 206 can extend from a distal end of the shaft 218 of the third body 206. The proximal struts 226 can be the most proximal struts of the third expandable framework 202.



FIG. 2C through 2E illustrate various configurations of the third body 206. In FIGS. 2C through 2E, the third plurality of struts 204 can be configured to form a substantially cylindrical body of interconnected struts. The third plurality of struts 204 can be interconnected with one another such that the third plurality of struts form a majority of closed cells. The third plurality of struts 204 can be configured to form closed cells of differing sizes and shapes. Optionally, the closed cells can be sized according to the content of the clot to be captured (e.g., based on how soft and/or fibrin rich the clot to be captured is). As illustrated in FIGS. 2C through 2E, the third body 206 can further include a plurality of clot reception spaces 230. The size of each clot reception space 230 can be based on the configuration of the third plurality of struts 204. Optionally, as illustrated in FIGS. 2C and 2E, the third plurality of struts 204 can include at least one disconnected strut 204 a. The disconnected strut can form an open cell. Such open cell can form a larger clot reception space 230, and thereby facilitate migration of the clot into the third body 206. Optionally, the third plurality of struts 204 can include a plurality of disconnected struts 204 a such that a majority of the cells are open cells. The third body 206 can serve two primary functions. For example, the third body 206 can facilitate allowing blood to pass through so that there is at least partial blood flow through the blood vessel as a clot is being captured and withdrawn by the clot retrieval device 200. Additionally, upon the clot retrieval device 200 being deployed, a clot can become partially integrated into the clot reception spaces 120 of the first body 110 and the second body 112. Upon the third body 206 moving (e.g., sliding) in relation to the first body 110 and the second body 112, the third body 206 can interact with the clot, thereby promoting further integration of the clot between the first body 110 and the second body 112 prior to forming a pinch.



FIG. 2F illustrates an additional side view of the clot retrieval device 200. As illustrated in FIG. 2F, the first body 110 can include a first collar 210, the second body 112 can include a second collar 212, and the third body 206 can include a third collar 214. Each collar 210, 212, 214 can facilitate moving (e.g., sliding) the third body 206 in relation to the first body 110 and the second body 112 and subsequently moving (e.g., sliding) the first body 110 in relation to the second body 112 to pinch at least a portion of a clot. The pull wire 114 can be affixed to the third body 206 and can be threaded through each collar 210, 212, 214 such that upon the pull wire 114 being pulled in the proximal direction, the clot retrieval device 200 can move (e.g., slide) from a first position to a second position and subsequently from a second position to a third position.



FIG. 2G illustrates an example third collar 214. The third collar 214 can be disposed where the expanded struts 208a, 208b conjoin. The third collar 214 can be laser cut in a particular design to facilitate pinching the clot upon the clot retrieval device 200 moving from the first position to the second position and subsequently from the second position to the third position.


In order to pinch the clot using the clot retrieval device 200, the pull wire 114 can be pulled in a proximal direction. Such tension can cause the third body 206 to move (e.g., slide) in relation to the first body 110 and the second body 112 causing the clot retrieval device 200 to transition from the first position to the second position, as indicated by a first arrow 232. For example, the third body 206 can slide less than approximately 5 millimeters in relation to the first body 110 and the second body 112. Optionally, the third body 206 can slide less than approximately 4 millimeters in relation to the first body 110 and the second body 112. Optionally, the third body 206 can slide less than approximately 2 millimeters in relation to the first body 110 and the second body 112. Optionally, the third body 206 can slide less than approximately 0.5 millimeters in relation to the first body and the second body 112.


Upon the third body 206 moving in relation to the first body 110 and the second body 112, at least a portion of the clot can be pinched between the third body 206 and the first body 110 and the second body 112 to cause the portions of the clot to migrate inside the first body 110 and the second body 112. Additionally, upon the third body 206 moving from the first position to the second position, the third body 206 can become engaged with the first body 110 as the third collar 214 becomes engaged with the first collar 210. When the third collar 214 and the first collar 210 become engaged, the pull force can be transferred to the first body 110, thereby allowing for further displacement.


Subsequently, the first body 110 can move (e.g., slide) in relation to the second body 112 such that the clot retrieval device 200 transitions from the second position to the third position, as indicated by a second arrow 234. For example, the first body 110 can slide less than approximately 5 millimeters in relation to the second body 112. Optionally, the first body 110 can slide less than approximately 4 millimeters in relation to the second body 112. Optionally, the first body 110 can slide less than approximately 2 millimeters in relation to the second body 112. Optionally, the first body 110 can slide less than approximately 0.5 millimeters in relation to the second body 112.


Upon the first body 110 moving from the second position to the third position, the first body 110 engaged with the third body 206 can become engaged with the second body 112 causing an average cross-sectional area of the plurality of clot reception spaces 120 to decrease (e.g., at least partially close). Thereby, at least a portion of the clot can be further pinched. The portions of the clot can be pinched between the first body 110 and the second body 112 and, additionally, the third body 206. Accordingly, the portions of the clot can further migrate inside third body 206. As such, the portions of the clot can further migrate into the clot reception spaces 230 of the third body 206. Upon transitioning to the third position, the expanded struts 208a, 208b can become resheathed as the first collar 210 becomes engaged with the second collar 212. When the first collar 210 becomes engaged with the second collar 212, the pull force can be transferred to the second body 112. Accordingly, the first body 110, the second body 112, and the third body 206, including the captured clot or portions thereof, can be removed simultaneously from the patient's vasculature.


Optionally, the clot retrieval device 200 can include a seal that allows the clot retrieval device 200 to maintain a pinch even if the physician stops applying tension. For example, the clot retrieval device 200 can include a seal disposed proximate the weld joint 220. The seal can maintain the clot retrieval device 200 in place using friction. As such, the seal can create enough static friction such that the clot removal device 200 does not displace when a physician stops applying tension while also ensuring the static friction is not too high that a user cannot overcome such static friction when manipulating the clot retrieval device 200 during retrieval of the clot and removal of the clot retrieval device 200 from a patient.



FIGS. 3A and 3B illustrate an additional example clot retrieval device 300. The clot retrieval device 300 can have a constrained delivery configuration and a clot engaging configuration and can be configured to remove a clot (e.g., thrombus) T from a blood vessel. The clot removal device 300 can be in the constrained delivery configuration when the clot removal device 300 is positioned within a restraining sheath (e.g., microcatheter). Upon the restraining sheath being retracted, the clot removal device 300 can transition to the clot engaging configuration. The clot retrieval device 300 can include an inner expandable framework 302 and an outer expandable framework 304. The inner expandable framework 302 can include an inner plurality of struts 306 that self-expand to form an inner body 310 upon the clot retrieval device 300 transitioning from the constrained delivery configuration to the clot engaging configuration. Similarly, the outer expandable framework 304 can include an outer plurality of struts 308 that self-expand form an outer body 312 upon the clot retrieval device 300 transitioning from the constrained delivery configuration to the clot engaging configuration. The inner expandable framework 302 and the outer expandable framework 304 can be preferably made from a material capable of recovering its shape automatically once released from a constricted delivery configuration and further include the additional characteristics as described above with reference to the first expandable framework 102 and the second expandable framework 104.


The inner body 310 and the outer body 312 can have different inner diameters 330, 332 and/or configurations. For example, the inner body 310 can have a smaller inner diameter 330 than the inner diameter 332 of the outer body 312, as such the outer body 312 can radially surround the inner body 310. Optionally, the inner diameter 330 of the inner body 310 can be approximately half of the size of the inner diameter 332 of the outer body 312. Optionally, the inner diameter 330 of the inner body 310 can be approximately ¾ of the size of the inner diameter 332 of the outer body 312. As illustrated in FIG. 3A, the differing diameters 330, 332 and shape configurations of the inner body 310 and the outer body 312 can form a plurality of clot reception spaces 320 configured to engage with a clot T. For example, the outer body 312 can include a plurality of scaffolding sections. A clot reception space 320 can be formed between each scaffolding section 338 of the plurality of scaffolding sections. Additionally, the inner body 310 can have a substantially “S” wave shape. Such “S” wave shape can facilitate pinching and capturing the clot upon the inner body 310 moving in relation to the outer body 312, and upon capturing the clot, preventing the captured clot from migrating out of the clot retrieval device 300.


The inner body 310 and the outer body 312 can each be affixed to a pull wire 314. The pull wire 314 can include a first stopper 322 and a second stopper 324 at a proximal end 326 of the pull wire. The first stopper 322 can be disposed distally in relation to the second stopper 324.


A spring 316 can be affixed to a distal end 318 of the pull wire 314. The spring 316 can be configured to transition from a compressed configuration and an elongated configuration upon actuation. The spring 316 can be configured to maintain a central position of the inner body 310 within the outer body 312. In the previously illustrated clot retrieval devices 100, 200 because the first body 110 has an approximately equal inner diameter 134 to the second body 112, the first body 110 resides centrally within the second body 112 because of outward force from the first body 110 onto the second body 112. When the inner body 310 has a substantially smaller inner diameter 330 than the outer body 312 as illustrated in FIGS. 3A and 3B, a distal portion of the inner body 310 can radially deflect with respect to the outer body 312 but for the spring 316 which inhibits the distal portion from deflecting. The spring 316 can further function to hold the device 300 in a first position when the pull wire 314 is not under tension.


As illustrated in FIG. 3A, the clot retrieval device 300 can be positioned proximate to the clot T. At least a portion of the clot retrieval device 300 can traverse the clot T such that a distal end of the clot retrieval device 300 can be forward in relation to the clot T. The pull wire 314 can be pulled in a proximal direction causing the inner body 310 to move (e.g., slide) from the first position to the second position in relation to the outer body 312.



FIG. 3B illustrates the clot retrieval device 300 transitioning to a clot pinching configuration upon the inner body 310 moving from the first position to the second position. The pull wire 314 can be pulled in the proximal direction until the first stopper 322 is proximate and/or engages (e.g., touches or becomes within a predetermined distance of the second stopper 324) the second stopper 324, as such the second stopper 324 can serve as an indicator of when to stop applying tension to the pull wire 314 and/or gradually weaken the amount of tension being applied to the pull wire 314. When the pull wire 314 is pulled in the proximal direction, the spring 316 can be actuated, causing the spring 316 to transition from the compressed configuration to the elongated configuration. When the spring 316 transitions to the elongated configuration, the inner body 310 can move from the first position to the second position. Such movement from the first position to the second position can cause the average cross-sectional area of the clot reception spaces 320 to decrease (e.g., at least partially close), thereby pinching the clot T between the inner body 310 and the outer body 312. Upon pinching the clot T between the inner body 310 and outer body 312, the inner body 310 and the outer body 312, including the clot T, can be retracted into the restraining sheath (e.g., microcatheter), and subsequently the clot retrieval device 300 can be removed from the patient.



FIG. 4 illustrates a flow diagram outlining a method 400 of capturing a clot using the clot retrieval device 100 illustrated in FIGS. 1A through 1G. The method 400 can include deploying 402 the clot retrieval device 100 proximate to the clot. As discussed herein, the clot retrieval device 100 can include a first expandable framework 102 and a second expandable framework 104. Upon deploying the clot retrieval device 100, the clot retrieval device 100 can transition from a constrained delivery configuration to a clot engaging configuration and the first expandable framework 102 can expand to form a first body 110 while the second expandable framework 104 can expand to form a second body 112 that radially surrounds the first body 110. The first body 110 and the second body 112 can have substantially the same inner diameter 134. 136, such that the first body 110 and the second body 112 substantially radially align with one another.


The method 400 can further include moving 404 (e.g., sliding) the first body 110 proximally in relation to the second body 112 to pinch at least a portion of the clot between the first body 110 and the second body 112 such that the clot removal device 100 transitions to a clot pinching configuration. By way of example, tension can be applied to the pull wire 114 until the first body 110 encounters the joint 130. As the pull wire 114 is pulled in the proximal direction, the first body 110 can move in the proximal direction in relation to the second body 112, thereby pinching at least a portion of the clot between the first body 110 and the second body 112.


The method 400 can further include capturing 406 one or more fragments of the clot.


Additionally, the method 400 can include retracting the first body 110 and the second body 112 simultaneously, as the first body 110 and the second body 112 become engaged upon the first body 110 moving in relation to the second body 112. Similarly, upon the first body 110 and the second body 112 being retracted into a restraining sheath, the restraining sheath can be removed from a patient's vasculature.



FIG. 5 illustrates a flow diagram outlining a method 500 of capturing a clot using the clot retrieval device 200 illustrated in FIGS. 2A through 2F. The method 500 can include deploying 502 the clot retrieval device 200 proximate to the clot. As discussed herein, the clot retrieval device 100 can include a first expandable framework 102, a second expandable framework 104, and a third expandable framework 202. Upon deploying the clot retrieval device 200, the clot retrieval device 200 can transition from a constrained delivery configuration to a clot engaging configuration and the first expandable framework 102 can expand to form a first body 110 while the second expandable framework 104 can expand to form a second body 112 that radially surrounds the first body 110. The first body 110 and the second body 112 can have substantially the same inner diameter 134. 136, such that the first body 110 and the second body 112 can substantially align with each other. Similarly, the third expandable framework 202 can expand to form the third body 206. The first body 110 and the second body 112 can radially surround the third body 206, as the third body 206 can have a smaller inner diameter 238 as compared to the first body 110 and the second body 112.


The method 500 can further include moving 504 (e.g., sliding) the third body 206 in relation to the first body 110 and the second body 112 to pinch at least a portion of the clot between the third body 206 and the first body 110 and the second body 112 such that the clot removal device 200 transitions to a clot pinching configuration. As such, at least a portion of the clot can migrate into the first body 110 and the second body 112. Upon moving the third body 206 in relation to the first body 110 and the second body 112, the third body 206 can become engaged with the first body 110.


The method 500 can further include moving 506 (e.g., sliding) the first body 110 proximally in relation to the second body 112 to further pinch at least a portion of the clot between the third body 206 and the first body 110 and the second body 112. As the first body 110 moves in relation to the second body 112, the average cross-sectional area of the clot reception spaces 120 can decrease, thereby pinching at least a portion of clot and preventing and/or mitigating the captured portions of the clot from migrating back out of the clot retrieval device 200. Upon pinching the clot, at least a portion of the clot can migrate inside the third body 206. When at least a portion of the clot is within third body 206, the potential for the portions of the captured clot to migrate back out of the clot retrieval device 200 can decrease.


The method 500 can further include capturing 508 one or more fragments of the clot.


Additionally, the method 500 can include simultaneously retracting the first body 110, the second body 112, and the third body 206. Upon being retracted into a delivery microcatheter, the delivery microcatheter can be removed from a patient's vasculature, and thus, the clot can be removed effectively and efficiently from the patient's vasculature.


Certain examples and implementations of the disclosed technology are described above with reference to block and flow diagrams according to examples of the disclosed technology. It will be understood that one or more blocks of the block diagrams and flow diagrams, and combinations of blocks in the block diagrams and flow diagrams, respectively. Likewise, some blocks of the block diagrams and flow diagrams do not necessarily need to be performed in the order presented, can be repeated, or do not necessarily need to be performed at all, according to some examples or implementations of the disclosed technology. It is also to be understood that the mention of one or more method steps does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified. Additionally, method steps from one process flow diagram or block diagram can be combined with method steps from another process diagram or block diagram. These combinations and/or modifications are contemplated herein.

Claims
  • 1. A clot retrieval device comprising a constrained delivery configuration and a clot engaging configuration and being configured to remove a clot from a blood vessel, the device comprising: a first expandable framework comprising a closed distal end, a closed proximal end, and a first plurality of struts forming a substantially cylindrical first body comprising a plurality of cells having two or more different shapes;a second expandable framework comprising a closed distal end, a closed proximal end, and a second plurality of struts forming a substantially cylindrical second body comprising a plurality of cells having two or more different shapes, a length of the second body at least partially surrounding and substantially aligned with a length of the first body; anda third expandable framework comprising a third plurality of struts forming a third body, the first body and the second body at least partially surrounding the third body in the clot engaging configuration,wherein in the clot engaging configuration, the first body is configured to move proximally from a first position to a second position in relation to the second body to compress at least a portion of the clot between the plurality of cells of the first body and the plurality of cells of the second body, andwherein the third body is configured to move in relation to the first body and the second body.
  • 2. The clot retrieval device of claim 1, wherein the first body has a first inner diameter and the second body has a second inner diameter, the first inner diameter and the second inner diameter being substantially equal.
  • 3. The clot retrieval device of claim 1, wherein when the first body is in the first position, the first plurality of struts and the second plurality of struts are disengaged such that a plurality of clot reception spaces are formed.
  • 4. The clot retrieval device of claim 3, wherein when the first body is in the second position, the first plurality of struts and the second plurality of struts are engaged such that an average cross-sectional area of the plurality of clot reception spaces decreases upon movement of the first body from the first position to the second position.
  • 5. The clot retrieval device of claim 1, wherein the first plurality of struts comprises at least one radially extending strut and the second plurality of struts comprises at least one eyelet through which the at least one radially extending strut radially extends, the at least one eyelet and the at least one radially extending strut being configured such that when the first body moves from the first position to the second position, the at least one radially extending strut engages the at least one eyelet to inhibit the first plurality of struts from moving, in relation to the second plurality of struts, beyond the second position.
  • 6. The clot retrieval device of claim 5, wherein each eyelet is tapered.
  • 7. The clot retrieval device of claim 1, further comprising a polymer coating to engage the first plurality of struts and the second plurality of struts, the polymer coating configured to fail to allow the first body to move from the first position to the second position.
  • 8. The clot retrieval device of claim 1, further comprising at least one polymer membrane, wherein a first polymer membrane is affixed to the first plurality of struts and the second plurality of struts such that the first polymer membrane is disposed between the first body and the second body.
  • 9. The clot retrieval device of claim 8, wherein the first polymer membrane is in a folded configuration when the first body is in the first position and the first polymer membrane transitions to a stretched configuration when the first body moves proximally to the second position.
  • 10. The clot retrieval device of claim 1, wherein a proximal end of the clot retrieval device includes a plurality of expanded struts that form a collar.
  • 11. The clot retrieval device of claim 1, wherein the third plurality of struts includes at least one disconnected strut.
  • 12. The clot retrieval device of claim 1, wherein the third body comprises a plurality of clot reception spaces, the plurality of clot reception spaces configured to engage the clot.
  • 13. A clot retrieval device comprising a constrained delivery configuration and a clot engaging configuration and being configured to remove a clot from a blood vessel, the device comprising: an inner expandable framework affixed to a pull wire and comprising a closed distal end, a closed proximal end, and an inner plurality of struts forming a substantially cylindrical inner body comprising a plurality of cells having two or more different shapes;an outer expandable framework affixed to the pull wire and comprising a closed distal end, a closed proximal end, and an outer plurality of struts forming a substantially cylindrical outer body comprising a plurality of cells having two or more different shapes, a length of the outer body at least partially surrounding and substantially aligned with a length of the inner body; anda spring affixed proximate to a distal end of the pull wire, the spring having a compressed configuration and an elongated configuration,wherein in the clot engaging configuration, the inner body is configured to move proximally from a first position to a second position in relation to the outer body such that the spring transitions from the compressed configuration to the elongated configuration and at least a portion of the clot is compressed between the plurality of cells of the inner body and the plurality of cells of the outer body.
  • 14. The clot retrieval device of claim 13, wherein the outer expandable framework comprises a plurality of clot reception spaces configured to pinch the clot between the inner body and the outer body when the inner body moves from the first position to the second position.
  • 15. A method of capturing a clot, the method comprising: deploying a clot retrieval device proximate to the clot, the clot retrieval device comprising: a first expandable framework comprising a closed distal end, a closed proximal end, and a first plurality of struts forming a substantially cylindrical body comprising a plurality of cells having two or more different shapes;a second expandable framework comprising a closed distal end, a closed proximal end, and a second plurality of struts forming a second substantially cylindrical body comprising a plurality of cells having two or more different shapes, a length of the second body at least partially surrounding and substantially aligned with a length of the first body; anda third expandable framework comprising a third plurality of struts forming a third body, the first body and the second body at least partially surrounding the third body in a clot engaging configuration, the third body configured to move in relation to the first body and the second body;moving the first body proximally in the clot engaging configuration in relation to the second body to pinch at least a portion of the clot between the plurality of cells of the first body and the plurality of cells of the second body; andcapturing one or more fragments of the clot.
  • 16. The method of claim 15, wherein moving the first body in relation to the second body to pinch at least a portion of the clot between the first body and the second body includes applying tension to a pull wire, the pull wire being in mechanical communication with the first body.
  • 17. The method of claim 15, further comprising retracting the first body and the second body simultaneously.
  • 18. The method of claim 15, further comprising: retracting the third body in a proximal direction to engage the first body and the second body.
US Referenced Citations (941)
Number Name Date Kind
2828147 Peiffer Dec 1899 A
3361460 Gerhart et al. Jan 1968 A
4455717 Gray Jun 1984 A
4611594 Grayhack et al. Sep 1986 A
4612931 Dormia Sep 1986 A
4643184 Mobin-Uddin Feb 1987 A
4727873 Mobin-Uddin Mar 1988 A
4793348 Palmaz Dec 1988 A
4873978 Ginsburg Oct 1989 A
5011488 Ginsburg Apr 1991 A
5084065 David et al. Jan 1992 A
5092839 Kipperman Mar 1992 A
5100423 Fearnot Mar 1992 A
5102415 Guenther et al. Apr 1992 A
5108419 Reger et al. Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5163951 Pinchuk et al. Nov 1992 A
5171233 Amplatz et al. Dec 1992 A
5171259 Inoue Dec 1992 A
5217441 Shichman Jun 1993 A
5234437 Sepetka Aug 1993 A
5236447 Kubo et al. Aug 1993 A
5330482 Gibbs et al. Jul 1994 A
5383887 Nadal Jan 1995 A
5387219 Rappe Feb 1995 A
5387226 Miraki Feb 1995 A
5449372 Schmaltz et al. Sep 1995 A
5499985 Hein et al. Mar 1996 A
5538512 Zenzon et al. Jul 1996 A
5538515 Kafry et al. Jul 1996 A
5549626 Miller et al. Aug 1996 A
5558652 Henke Sep 1996 A
5609627 Goicoechea et al. Mar 1997 A
5624461 Mariant Apr 1997 A
5639277 Mariant et al. Jun 1997 A
5639278 Dereume et al. Jun 1997 A
5645558 Horton Jul 1997 A
5653605 Woehl et al. Aug 1997 A
5658296 Bates et al. Aug 1997 A
5665117 Rhodes Sep 1997 A
5695519 Summers et al. Dec 1997 A
5709704 Nott et al. Jan 1998 A
5713853 Clark et al. Feb 1998 A
5733325 Robinson et al. Mar 1998 A
5769871 Mers Kelly et al. Jun 1998 A
5769884 Solovay Jun 1998 A
5779686 Sato et al. Jul 1998 A
5779716 Cano et al. Jul 1998 A
5800519 Sandock Sep 1998 A
5810874 Lefebvre Sep 1998 A
5814064 Daniel et al. Sep 1998 A
5824041 Lenker et al. Oct 1998 A
5827304 Hart Oct 1998 A
5853422 Huebsch et al. Dec 1998 A
5855598 Pinchuk Jan 1999 A
5893869 Barnhart et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5897567 Ressemann et al. Apr 1999 A
5904698 Thomas et al. May 1999 A
5911702 Romley et al. Jun 1999 A
5911725 Boury Jun 1999 A
5919126 Armini Jul 1999 A
5931509 Bartholomew Aug 1999 A
5935139 Bates Aug 1999 A
5947995 Samuels Sep 1999 A
6063113 Kavteladze et al. May 2000 A
6066149 Samson et al. May 2000 A
6066158 Engelson et al. May 2000 A
6093196 Okada Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096053 Bates Aug 2000 A
6099534 Bates et al. Aug 2000 A
6099559 Nolting Aug 2000 A
6102932 Kurz Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6129739 Khosravi Oct 2000 A
6143022 Shull et al. Nov 2000 A
6146404 Kim et al. Nov 2000 A
6156064 Chouinard Dec 2000 A
6165194 Denardo Dec 2000 A
6165199 Barbut Dec 2000 A
6168604 Cano Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6174318 Bates et al. Jan 2001 B1
6179861 Khosravi et al. Jan 2001 B1
6203561 Ramee et al. Mar 2001 B1
6214026 Lepak et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6231597 Deem et al. May 2001 B1
6238412 Dubrul et al. May 2001 B1
6245012 Kleshinski Jun 2001 B1
6245087 Addis Jun 2001 B1
6251122 Tsukernik Jun 2001 B1
6254571 Hart Jul 2001 B1
6264663 Cano Jul 2001 B1
6267777 Bosma et al. Jul 2001 B1
6290710 Cryer et al. Sep 2001 B1
6312444 Barbut Nov 2001 B1
6315778 Gambale et al. Nov 2001 B1
6325815 Kusleika et al. Dec 2001 B1
6325819 Pavcnik et al. Dec 2001 B1
6334864 Amplatz et al. Jan 2002 B1
6336934 Gilson et al. Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348056 Bates et al. Feb 2002 B1
6350271 Kurz et al. Feb 2002 B1
6355057 DeMarais et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6383205 Samson et al. May 2002 B1
6383206 Gillick et al. May 2002 B1
6391037 Greenhalgh May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6416541 Denardo Jul 2002 B2
6425909 Dieck et al. Jul 2002 B1
6428558 Jones et al. Aug 2002 B1
6432122 Gilson et al. Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6458139 Palmer et al. Oct 2002 B1
6485497 Wensel et al. Nov 2002 B2
6485501 Green Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6488701 Nolting et al. Dec 2002 B1
6511492 Rosenbluth et al. Jan 2003 B1
6530935 Wensel et al. Mar 2003 B2
6530939 Hopkins et al. Mar 2003 B1
6540768 Diaz et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6551341 Boylan et al. Apr 2003 B2
6551342 Shen et al. Apr 2003 B1
6575996 Denison et al. Jun 2003 B1
6575997 Palmer et al. Jun 2003 B1
6582448 Boyle et al. Jun 2003 B1
6585756 Strecker Jul 2003 B1
6589265 Palmer et al. Jul 2003 B1
6592607 Palmer et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6592616 Stack et al. Jul 2003 B1
6598265 Lee Jul 2003 B2
6602265 Dubrul et al. Aug 2003 B2
6602271 Adams et al. Aug 2003 B2
6602272 Boylan et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616679 Khosravi et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6638245 Miller et al. Oct 2003 B2
6638293 Makower et al. Oct 2003 B1
6641590 Palmer et al. Nov 2003 B1
6656218 Denardo et al. Dec 2003 B1
6660021 Palmer et al. Dec 2003 B1
6663650 Sepetka et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6685722 Rosenbluth et al. Feb 2004 B1
6692504 Kurz et al. Feb 2004 B2
6692508 Wensel et al. Feb 2004 B2
6692509 Wensel et al. Feb 2004 B2
6695858 Dubrul et al. Feb 2004 B1
6702782 Miller et al. Mar 2004 B2
6702834 Boylan et al. Mar 2004 B1
6709465 Mitchell et al. Mar 2004 B2
6712834 Yassour et al. Mar 2004 B2
6726701 Gilson et al. Apr 2004 B2
6726703 Broome et al. Apr 2004 B2
6730104 Sepetka et al. May 2004 B1
6783528 Vincent-Prestigiacomo Aug 2004 B2
6783538 McGuckin, Jr. et al. Aug 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6855155 Denardo et al. Feb 2005 B2
6878163 Denardo et al. Apr 2005 B2
6890340 Duane May 2005 B2
6913612 Palmer et al. Jul 2005 B2
6913618 Denardo et al. Jul 2005 B2
6939361 Kleshinski Sep 2005 B1
6953472 Palmer et al. Oct 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
6989021 Bosma et al. Jan 2006 B2
6994718 Groothuis et al. Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7004955 Shen et al. Feb 2006 B2
7004956 Palmer et al. Feb 2006 B2
7008434 Kurz et al. Mar 2006 B2
7033376 Tsukernik Apr 2006 B2
7041116 Goto et al. May 2006 B2
7048758 Boyle et al. May 2006 B2
7052500 Bashiri et al. May 2006 B2
7058456 Pierce Jun 2006 B2
7063707 Bose et al. Jun 2006 B2
7083633 Morrill et al. Aug 2006 B2
7083822 Brightbill Aug 2006 B2
7094249 Broome et al. Aug 2006 B1
7097653 Freudenthal et al. Aug 2006 B2
7101380 Khachin et al. Sep 2006 B2
7172614 Boyle et al. Feb 2007 B2
7175655 Molaei Feb 2007 B1
7179273 Palmer et al. Feb 2007 B1
7185922 Takayanagi et al. Mar 2007 B2
7220271 Clubb et al. May 2007 B2
7226464 Garner et al. Jun 2007 B2
7229472 DePalma et al. Jun 2007 B2
7241304 Boyle et al. Jul 2007 B2
7241308 Andreas et al. Jul 2007 B2
7288112 Denardo et al. Oct 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7314483 Andau et al. Jan 2008 B2
7316692 Huffmaster Jan 2008 B2
7323001 Clubb et al. Jan 2008 B2
7331976 McGuckin, Jr. et al. Feb 2008 B2
7344550 Carrison et al. Mar 2008 B2
7399308 Borillo et al. Jul 2008 B2
7410491 Hopkins et al. Aug 2008 B2
7425215 Boyle et al. Sep 2008 B2
7452496 Brady et al. Nov 2008 B2
7491215 Vale et al. Feb 2009 B2
7491216 Brady Feb 2009 B2
7510565 Gilson et al. Mar 2009 B2
7534252 Sepetka et al. May 2009 B2
7556636 Mazzocchi et al. Jul 2009 B2
7582111 Krolik et al. Sep 2009 B2
7594926 Linder et al. Sep 2009 B2
7604649 McGuckin, Jr. et al. Oct 2009 B2
7604650 Bergheim Oct 2009 B2
7609649 Bhandari et al. Oct 2009 B1
7618434 Santra et al. Nov 2009 B2
7662165 Gilson et al. Feb 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678123 Chanduszko Mar 2010 B2
7691121 Rosenbluth et al. Apr 2010 B2
7691124 Balgobin Apr 2010 B2
7708770 Linder et al. May 2010 B2
7717929 Fallman May 2010 B2
7736385 Agnew Jun 2010 B2
7749246 McGuckin, Jr. et al. Jul 2010 B2
7758606 Streeter et al. Jul 2010 B2
7758611 Kato Jul 2010 B2
7766934 Pal et al. Aug 2010 B2
7771452 Pal et al. Aug 2010 B2
7780694 Palmer et al. Aug 2010 B2
7780700 Frazier et al. Aug 2010 B2
7811305 Balgobin et al. Oct 2010 B2
7815659 Conlon et al. Oct 2010 B2
7819893 Brady et al. Oct 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7833240 Okushi et al. Nov 2010 B2
7842053 Chanduszko et al. Nov 2010 B2
7846175 Bonnette et al. Dec 2010 B2
7846176 Gilson et al. Dec 2010 B2
7850708 Pal Dec 2010 B2
7883516 Huang et al. Feb 2011 B2
7887560 Kusleika Feb 2011 B2
7901426 Gilson et al. Mar 2011 B2
7914549 Morsi Mar 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7927784 Simpson Apr 2011 B2
7931659 Bose et al. Apr 2011 B2
7998165 Huffmaster Aug 2011 B2
8002822 Glocker et al. Aug 2011 B2
8021379 Thompson et al. Sep 2011 B2
8021380 Thompson et al. Sep 2011 B2
8043326 Hancock et al. Oct 2011 B2
8048151 OBrien et al. Nov 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057497 Raju et al. Nov 2011 B1
8057507 Horan et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8109941 Richardson Feb 2012 B2
8118829 Carrison et al. Feb 2012 B2
8118856 Schreck et al. Feb 2012 B2
8123769 Osborne Feb 2012 B2
8137376 Clubb et al. Mar 2012 B2
8137377 Palmer et al. Mar 2012 B2
8142422 Makower et al. Mar 2012 B2
8142442 Palmer et al. Mar 2012 B2
8182508 Magnuson et al. May 2012 B2
8187298 Pal May 2012 B2
8246641 Osborne et al. Aug 2012 B2
8246672 Osborne Aug 2012 B2
8252017 Paul, Jr. et al. Aug 2012 B2
8252018 Valaie Aug 2012 B2
8262689 Schneiderman et al. Sep 2012 B2
8282668 McGuckin, Jr. et al. Oct 2012 B2
8287538 Brenzel et al. Oct 2012 B2
8298257 Sepetka et al. Oct 2012 B2
RE43882 Hopkins et al. Dec 2012 E
8357178 Grandfield et al. Jan 2013 B2
8357179 Grandfield et al. Jan 2013 B2
8357180 Feller, III et al. Jan 2013 B2
8357893 Xu et al. Jan 2013 B2
8361095 Osborne Jan 2013 B2
8361110 Chanduszko Jan 2013 B2
8366663 Fiorella et al. Feb 2013 B2
8409215 Sepetka et al. Apr 2013 B2
8414482 Belson Apr 2013 B2
8414543 McGuckin, Jr. et al. Apr 2013 B2
8419748 Valaie Apr 2013 B2
8460312 Bose et al. Jun 2013 B2
8460313 Huffmaster Jun 2013 B2
8486104 Samson et al. Jul 2013 B2
8512352 Martin Aug 2013 B2
8529596 Grandfield et al. Sep 2013 B2
8545526 Martin et al. Oct 2013 B2
8574262 Ferrera et al. Nov 2013 B2
8574915 Zhang et al. Nov 2013 B2
8579915 French et al. Nov 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8608761 Osborne et al. Dec 2013 B2
8679142 Slee et al. Mar 2014 B2
8690907 Janardhan et al. Apr 2014 B1
8696622 Fiorella et al. Apr 2014 B2
8702652 Fiorella et al. Apr 2014 B2
8702704 Shelton, IV et al. Apr 2014 B2
8702724 Olsen et al. Apr 2014 B2
8777919 Kimura et al. Jul 2014 B2
8777976 Brady et al. Jul 2014 B2
8777979 Shrivastava et al. Jul 2014 B2
8784434 Rosenbluth et al. Jul 2014 B2
8784441 Rosenbluth et al. Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795317 Grandfield et al. Aug 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8814892 Galdonik et al. Aug 2014 B2
8814925 Hilaire et al. Aug 2014 B2
8852205 Brady et al. Oct 2014 B2
8870941 Evans et al. Oct 2014 B2
8900265 Ulm, III Dec 2014 B1
8920358 Levine et al. Dec 2014 B2
8939991 Krolik et al. Jan 2015 B2
8945143 Ferrera et al. Feb 2015 B2
8945160 Krolik et al. Feb 2015 B2
8945169 Pal Feb 2015 B2
8945172 Ferrera et al. Feb 2015 B2
8956399 Cam et al. Feb 2015 B2
8968330 Rosenbluth et al. Mar 2015 B2
9011481 Aggerholm et al. Apr 2015 B2
9039749 Shrivastava et al. May 2015 B2
9072537 Grandfield et al. Jul 2015 B2
9095342 Becking et al. Aug 2015 B2
9113936 Palmer et al. Aug 2015 B2
9119656 Bose et al. Sep 2015 B2
9138307 Valaie Sep 2015 B2
9155552 Ulm, III Oct 2015 B2
9161758 Figulla et al. Oct 2015 B2
9161766 Slee et al. Oct 2015 B2
9173668 Ulm, III Nov 2015 B2
9173688 Dosta Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9198687 Fulkerson et al. Dec 2015 B2
9204887 Cully et al. Dec 2015 B2
9211132 Bowman Dec 2015 B2
9232992 Heidner et al. Jan 2016 B2
9254371 Martin et al. Feb 2016 B2
9301769 Brady et al. Apr 2016 B2
9332999 Ray et al. May 2016 B2
9402707 Brady et al. Aug 2016 B2
9445829 Brady et al. Sep 2016 B2
9456834 Folk Oct 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9532873 Kelley Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539011 Chen et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9539382 Nelson Jan 2017 B2
9549830 Bruszewski et al. Jan 2017 B2
9554805 Tompkins et al. Jan 2017 B2
9561125 Bowman et al. Feb 2017 B2
9572982 Burnes et al. Feb 2017 B2
9579104 Beckham et al. Feb 2017 B2
9579484 Barnell Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9615951 Bennett et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9636115 Henry et al. May 2017 B2
9636439 Chu et al. May 2017 B2
9642639 Brady et al. May 2017 B2
9642675 Werneth et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9655645 Staunton May 2017 B2
9655898 Palepu et al. May 2017 B2
9655989 Cruise et al. May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662238 Dwork et al. May 2017 B2
9662425 Lilja et al. May 2017 B2
9668898 Wong Jun 2017 B2
9675477 Thompson Jun 2017 B2
9675782 Connolly Jun 2017 B2
9676022 Ensign et al. Jun 2017 B2
9692557 Murphy Jun 2017 B2
9693852 Lam et al. Jul 2017 B2
9700262 Janik et al. Jul 2017 B2
9700399 Acosta-Acevedo Jul 2017 B2
9717421 Griswold et al. Aug 2017 B2
9717500 Tieu et al. Aug 2017 B2
9717502 Teoh et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9724526 Strother et al. Aug 2017 B2
9750565 Bloom et al. Sep 2017 B2
9757260 Greenan Sep 2017 B2
9758606 Lambert et al. Sep 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman et al. Sep 2017 B2
9770577 Li et al. Sep 2017 B2
9775621 Tompkins et al. Oct 2017 B2
9775706 Peterson et al. Oct 2017 B2
9775732 Khenansho Oct 2017 B2
9788800 Mayoras, Jr. Oct 2017 B2
9795391 Saatchi et al. Oct 2017 B2
9801651 Harrah et al. Oct 2017 B2
9801980 Karino et al. Oct 2017 B2
9808599 Bowman et al. Nov 2017 B2
9833252 Sepetka et al. Dec 2017 B2
9833304 Horan et al. Dec 2017 B2
9833604 Lam et al. Dec 2017 B2
9833625 Waldhauser et al. Dec 2017 B2
9901434 Hoffman Feb 2018 B2
9918720 Marchand et al. Mar 2018 B2
9939361 Gaji et al. Apr 2018 B2
10016206 Yang Jul 2018 B1
10070878 Ma Sep 2018 B2
10098651 Marchand et al. Oct 2018 B2
10201360 Vale et al. Feb 2019 B2
10231751 Sos Mar 2019 B2
10292723 Brady et al. May 2019 B2
10299811 Brady et al. May 2019 B2
10363054 Vale et al. Jul 2019 B2
10376274 Farin et al. Aug 2019 B2
10390850 Vale et al. Aug 2019 B2
10524811 Marchand et al. Jan 2020 B2
10531942 Eggers Jan 2020 B2
10617435 Vale et al. Apr 2020 B2
10722257 Skillrud et al. Jul 2020 B2
11439418 O'Malley Sep 2022 B2
11517340 Casey Dec 2022 B2
20010001315 Bates et al. May 2001 A1
20010016755 Addis Aug 2001 A1
20010037141 Yee et al. Nov 2001 A1
20010037171 Sato Nov 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010044632 Daniel et al. Nov 2001 A1
20010049554 Ruiz et al. Dec 2001 A1
20010051810 Dubrul et al. Dec 2001 A1
20020004667 Adams et al. Jan 2002 A1
20020016609 Wensel et al. Feb 2002 A1
20020022859 Ogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020042627 Brady et al. Apr 2002 A1
20020049468 Streeter et al. Apr 2002 A1
20020052620 Barbut May 2002 A1
20020058911 Gilson et al. May 2002 A1
20020068954 Foster Jun 2002 A1
20020072764 Sepetka et al. Jun 2002 A1
20020082558 Samson et al. Jun 2002 A1
20020091407 Zadno-Azizi Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020123765 Sepetka et al. Sep 2002 A1
20020128680 Pavolvic Sep 2002 A1
20020138094 Borillo et al. Sep 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020143362 Macoviak et al. Oct 2002 A1
20020156455 Barbut Oct 2002 A1
20020161393 Demond et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020173819 Eeflang et al. Nov 2002 A1
20020183787 Wahr et al. Dec 2002 A1
20020188276 Evans et al. Dec 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20020193824 Boylan et al. Dec 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20030004536 Boylan Jan 2003 A1
20030004538 Secrest et al. Jan 2003 A1
20030004540 Linder et al. Jan 2003 A1
20030004542 Wensel et al. Jan 2003 A1
20030009146 Muni et al. Jan 2003 A1
20030009191 Wensel et al. Jan 2003 A1
20030038447 Cantele Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030050663 Khachin et al. Mar 2003 A1
20030064151 Klinedinst Apr 2003 A1
20030069520 Skujins et al. Apr 2003 A1
20030108224 Ike Jun 2003 A1
20030114879 Euteneuer et al. Jun 2003 A1
20030125798 Martin Jul 2003 A1
20030130682 Broome et al. Jul 2003 A1
20030144687 Brady et al. Jul 2003 A1
20030144688 Brady et al. Jul 2003 A1
20030153158 Ho et al. Aug 2003 A1
20030153943 Michael et al. Aug 2003 A1
20030153944 Phung et al. Aug 2003 A1
20030163064 Vrba et al. Aug 2003 A1
20030163158 White Aug 2003 A1
20030171769 Barbut Sep 2003 A1
20030171771 Anderson et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030195537 Dubrul et al. Oct 2003 A1
20030195554 Shen et al. Oct 2003 A1
20030199917 Knudson et al. Oct 2003 A1
20030204202 Palmer et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212430 Bose et al. Nov 2003 A1
20030236533 Wilson et al. Dec 2003 A1
20040064179 Linder et al. Apr 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040079429 Miller et al. Apr 2004 A1
20040082962 Demarais et al. Apr 2004 A1
20040082967 Broome Apr 2004 A1
20040088001 Bosma et al. May 2004 A1
20040093065 Yachia et al. May 2004 A1
20040098050 Foerster et al. May 2004 A1
20040133231 Maitland et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138692 Phung et al. Jul 2004 A1
20040153117 Clubb et al. Aug 2004 A1
20040153118 Clubb et al. Aug 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040204749 Gunderson Oct 2004 A1
20040215318 Kwitkin Oct 2004 A1
20040220663 Rivelli Nov 2004 A1
20050010245 Wasicek Jan 2005 A1
20050033248 Machida et al. Feb 2005 A1
20050033348 Sepetka et al. Feb 2005 A1
20050038447 Huffmaster Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050049619 Sepetka et al. Mar 2005 A1
20050049669 Jones et al. Mar 2005 A1
20050049670 Jones et al. Mar 2005 A1
20050055033 Leslie et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050058837 Farnworth et al. Mar 2005 A1
20050059995 Sepetka et al. Mar 2005 A1
20050085849 Sepetka et al. Apr 2005 A1
20050090779 Osypka Apr 2005 A1
20050090857 Kusleika et al. Apr 2005 A1
20050125024 Sepetka et al. Jun 2005 A1
20050149997 Wolozin et al. Jul 2005 A1
20050171566 Kanamaru Aug 2005 A1
20050173135 Almen Aug 2005 A1
20050192627 Whisenant et al. Sep 2005 A1
20050215942 Abrahamson et al. Sep 2005 A1
20050216030 Sepetka et al. Sep 2005 A1
20050216050 Sepetka et al. Sep 2005 A1
20050228417 Teitelbaum et al. Oct 2005 A1
20050251206 Maahs et al. Nov 2005 A1
20050251209 Saadat et al. Nov 2005 A1
20050267491 Kellett et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20050283186 Berrada et al. Dec 2005 A1
20050288686 Sepetka et al. Dec 2005 A1
20060008332 Greenberg et al. Jan 2006 A1
20060009798 Callister et al. Jan 2006 A1
20060009799 Kleshinski et al. Jan 2006 A1
20060020285 Niermann Jan 2006 A1
20060020286 Niermann Jan 2006 A1
20060030877 Martinez et al. Feb 2006 A1
20060041228 Vo et al. Feb 2006 A1
20060058836 Bose et al. Mar 2006 A1
20060058837 Bose et al. Mar 2006 A1
20060058838 Bose et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060069424 Acosta et al. Mar 2006 A1
20060074477 Berthiaume et al. Apr 2006 A1
20060142838 Molaei et al. Jun 2006 A1
20060149313 Arguello et al. Jul 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060161187 Evine et al. Jul 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060224177 Finitsis Oct 2006 A1
20060224179 Kucharczyk et al. Oct 2006 A1
20060229638 Abrams et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060241677 Johnson et al. Oct 2006 A1
20060282111 Morsi Dec 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287701 Pal Dec 2006 A1
20060293706 Shimon Dec 2006 A1
20070010857 Sugimoto et al. Jan 2007 A1
20070032879 Levine et al. Feb 2007 A1
20070088382 Bei et al. Apr 2007 A1
20070088383 Pal Apr 2007 A1
20070100348 Cauthen, III et al. May 2007 A1
20070118173 Magnuson et al. May 2007 A1
20070149997 Muller Jun 2007 A1
20070156170 Hancock et al. Jul 2007 A1
20070165170 Fukuda Jul 2007 A1
20070179527 Eskuri et al. Aug 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070198051 Clubb et al. Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070208371 French et al. Sep 2007 A1
20070225749 Martin et al. Sep 2007 A1
20070233175 Zaver et al. Oct 2007 A1
20070244505 Gilson et al. Oct 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080045881 Teitelbaum et al. Feb 2008 A1
20080077227 Ouellette et al. Mar 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080086190 Ta Apr 2008 A1
20080091223 Pokorney et al. Apr 2008 A1
20080097386 Osypka Apr 2008 A1
20080109031 Sepetka et al. May 2008 A1
20080109032 Sepetka et al. May 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080125798 Osborne et al. May 2008 A1
20080177296 Sepetka et al. Jul 2008 A1
20080178890 Townsend et al. Jul 2008 A1
20080183197 Sepetka et al. Jul 2008 A1
20080183198 Sepetka et al. Jul 2008 A1
20080183205 Sepetka et al. Jul 2008 A1
20080188876 Sepetka et al. Aug 2008 A1
20080188885 Sepetka et al. Aug 2008 A1
20080188887 Batiste Aug 2008 A1
20080200946 Braun et al. Aug 2008 A1
20080200947 Kusleika et al. Aug 2008 A1
20080215077 Sepetka et al. Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234706 Sepetka et al. Sep 2008 A1
20080243170 Jenson et al. Oct 2008 A1
20080255596 Jenson et al. Oct 2008 A1
20080262410 Jenson et al. Oct 2008 A1
20080262528 Martin Oct 2008 A1
20080262532 Martin Oct 2008 A1
20080262590 Murray Oct 2008 A1
20080269871 Eli Oct 2008 A1
20080275488 Fleming Nov 2008 A1
20080275493 Farmiga Nov 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080312681 Ansel et al. Dec 2008 A1
20090005858 Young et al. Jan 2009 A1
20090024157 Anukhin Jan 2009 A1
20090030443 Buser et al. Jan 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090076539 Valaie Mar 2009 A1
20090088793 Bagaoisan et al. Apr 2009 A1
20090088795 Cahill Apr 2009 A1
20090105722 Fulkerson et al. Apr 2009 A1
20090105737 Fulkerson et al. Apr 2009 A1
20090105747 Chanduszko et al. Apr 2009 A1
20090149881 Vale et al. Jun 2009 A1
20090163851 Holloway et al. Jun 2009 A1
20090177206 Lozier et al. Jul 2009 A1
20090182336 Brenzel et al. Jul 2009 A1
20090281610 Parker Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287229 Ogdahl Nov 2009 A1
20090292297 Ferrere Nov 2009 A1
20090292307 Razack Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20090299403 Chanduszko et al. Dec 2009 A1
20090306702 Miloslavski et al. Dec 2009 A1
20090326636 Hashimoto et al. Dec 2009 A1
20100004607 Wilson et al. Jan 2010 A1
20100076482 Shu et al. Mar 2010 A1
20100087850 Razack Apr 2010 A1
20100087908 Hilaire et al. Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100125326 Kalstad et al. May 2010 A1
20100125327 Agnew May 2010 A1
20100191272 Keating Jul 2010 A1
20100211094 Sargent, Jr. Aug 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100268265 Krolik et al. Oct 2010 A1
20100274277 Eaton Oct 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20100324649 Mattsson et al. Dec 2010 A1
20100331949 Habib Dec 2010 A1
20110009875 Grandfield et al. Jan 2011 A1
20110009940 Grandfield et al. Jan 2011 A1
20110009950 Grandfield et al. Jan 2011 A1
20110015718 Schreck Jan 2011 A1
20110022149 Cox et al. Jan 2011 A1
20110040319 Fulton, III Feb 2011 A1
20110054287 Schultz Mar 2011 A1
20110054504 Porter Mar 2011 A1
20110054514 Arcand et al. Mar 2011 A1
20110054516 Keegan et al. Mar 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110060359 Hannes et al. Mar 2011 A1
20110106137 Shimon May 2011 A1
20110125181 Brady et al. May 2011 A1
20110152920 Eckhouse et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110166586 Sepetka et al. Jul 2011 A1
20110184456 Grandfield et al. Jul 2011 A1
20110196414 Porter et al. Aug 2011 A1
20110202088 Eckhouse et al. Aug 2011 A1
20110208233 McGuckin, Jr. et al. Aug 2011 A1
20110213297 Aklog et al. Sep 2011 A1
20110213393 Aklog et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110224707 Miloslavski et al. Sep 2011 A1
20110270374 Orr et al. Nov 2011 A1
20110276120 Gilson et al. Nov 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120041449 Eckhouse et al. Feb 2012 A1
20120041474 Eckhouse et al. Feb 2012 A1
20120059356 di Palma et al. Mar 2012 A1
20120065660 Ferrera et al. Mar 2012 A1
20120083823 Shrivastava et al. Apr 2012 A1
20120083868 Shrivastava et al. Apr 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120116440 Leynov et al. May 2012 A1
20120123466 Porter et al. May 2012 A1
20120022572 Braun et al. Jun 2012 A1
20120143230 Sepetka et al. Jun 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120143317 Cam et al. Jun 2012 A1
20120150147 Leynov et al. Jun 2012 A1
20120165858 Eckhouse et al. Jun 2012 A1
20120165859 Eckhouse et al. Jun 2012 A1
20120209312 Aggerholm et al. Aug 2012 A1
20120215250 Grandfield et al. Aug 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120296362 Cam et al. Nov 2012 A1
20120316600 Ferrera et al. Dec 2012 A1
20120330350 Jones et al. Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130030461 Marks et al. Jan 2013 A1
20130046330 McIntosh Feb 2013 A1
20130046333 Jones et al. Feb 2013 A1
20130046334 Jones et al. Feb 2013 A1
20130116774 Strauss et al. May 2013 A1
20130131614 Hassan et al. May 2013 A1
20130144311 Fung et al. Jun 2013 A1
20130144326 Brady et al. Jun 2013 A1
20130158591 Koehler Jun 2013 A1
20130158592 Porter Jun 2013 A1
20130184739 Brady et al. Jul 2013 A1
20130197567 Brady et al. Aug 2013 A1
20130226146 Tekulve Aug 2013 A1
20130268050 Wilson et al. Oct 2013 A1
20130271788 Utsunomiya Oct 2013 A1
20130277079 Tsuzuki et al. Oct 2013 A1
20130281788 Garrison Oct 2013 A1
20130325051 Martin et al. Dec 2013 A1
20130325055 Eckhouse et al. Dec 2013 A1
20130325056 Eckhouse et al. Dec 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140005712 Martin Jan 2014 A1
20140005713 Bowman Jan 2014 A1
20140046359 Bowman et al. Feb 2014 A1
20140088678 Wainwright et al. Mar 2014 A1
20140121672 Folk May 2014 A1
20140128905 Molaei May 2014 A1
20140134654 Rudel et al. May 2014 A1
20140135812 Divino et al. May 2014 A1
20140142598 Fulton, III May 2014 A1
20140163367 Eskuri Jun 2014 A1
20140180122 Stigall et al. Jun 2014 A1
20140180377 Bose et al. Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140183077 Rosendall et al. Jul 2014 A1
20140194911 Johnson et al. Jul 2014 A1
20140194919 Losordo et al. Jul 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140200608 Brady et al. Jul 2014 A1
20140236220 Inoue Aug 2014 A1
20140243881 Lees et al. Aug 2014 A1
20140257362 Eidenschink Sep 2014 A1
20140276922 McLain et al. Sep 2014 A1
20140277079 Vale et al. Sep 2014 A1
20140303667 Cox et al. Oct 2014 A1
20140309657 Ben-Ami Oct 2014 A1
20140309673 Dacuycuy et al. Oct 2014 A1
20140330302 Tekulve et al. Nov 2014 A1
20140343585 Ferrera et al. Nov 2014 A1
20140371769 Vale et al. Dec 2014 A1
20140371779 Vale et al. Dec 2014 A1
20140371780 Vale et al. Dec 2014 A1
20140372779 Wong et al. Dec 2014 A1
20140379023 Brady et al. Dec 2014 A1
20150018859 Quick et al. Jan 2015 A1
20150018860 Quick et al. Jan 2015 A1
20150032144 Holloway Jan 2015 A1
20150080937 Davidson Mar 2015 A1
20150112376 Molaei et al. Apr 2015 A1
20150133990 Davidson May 2015 A1
20150150672 Ma Jun 2015 A1
20150164523 Brady et al. Jun 2015 A1
20150224133 Ohri et al. Aug 2015 A1
20150250497 Marks et al. Sep 2015 A1
20150257775 Gilvarry et al. Sep 2015 A1
20150272716 Pinchuk et al. Oct 2015 A1
20150297252 Miloslavski et al. Oct 2015 A1
20150313617 Grandfield et al. Nov 2015 A1
20150320431 John Nov 2015 A1
20150352325 Quick Dec 2015 A1
20150359547 Vale et al. Dec 2015 A1
20150366650 Zi et al. Dec 2015 A1
20150374391 Quick et al. Dec 2015 A1
20150374393 Brady et al. Dec 2015 A1
20150374479 Vale Dec 2015 A1
20160015402 Brady et al. Jan 2016 A1
20160022269 Ganske et al. Jan 2016 A1
20160022296 Brady et al. Jan 2016 A1
20160045298 Thinnes, Jr. et al. Feb 2016 A1
20160066921 Seifert et al. Mar 2016 A1
20160100928 Lees et al. Apr 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113664 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160120558 Brady et al. May 2016 A1
20160143653 Vale et al. May 2016 A1
20160192953 Brady et al. Jul 2016 A1
20160192954 Brady et al. Jul 2016 A1
20160192955 Brady et al. Jul 2016 A1
20160192956 Brady et al. Jul 2016 A1
20160256180 Vale et al. Sep 2016 A1
20160303381 Pierce et al. Oct 2016 A1
20160317168 Brady et al. Nov 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007265 Guo et al. Jan 2017 A1
20170020542 Martin et al. Jan 2017 A1
20170020670 Murray et al. Jan 2017 A1
20170020700 Bienvenu et al. Jan 2017 A1
20170027640 Kunis et al. Feb 2017 A1
20170027692 Bonhoeffer et al. Feb 2017 A1
20170027725 Argentine Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035567 Duffy Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170049596 Schabert Feb 2017 A1
20170056061 Ogle et al. Mar 2017 A1
20170071614 Vale et al. Mar 2017 A1
20170071737 Kelley Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079671 Morero et al. Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079766 Wang et al. Mar 2017 A1
20170079767 Leon-Yip Mar 2017 A1
20170079812 Am et al. Mar 2017 A1
20170079817 Sepetka et al. Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170086851 Wallace et al. Mar 2017 A1
20170086862 Vale et al. Mar 2017 A1
20170086863 Brady et al. Mar 2017 A1
20170086996 Peterson et al. Mar 2017 A1
20170095259 Tompkins et al. Apr 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170100141 Morero et al. Apr 2017 A1
20170100143 Grandfield Apr 2017 A1
20170100183 Aizzo et al. Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170112515 Brady et al. Apr 2017 A1
20170112647 Sachar et al. Apr 2017 A1
20170113023 Steingisser et al. Apr 2017 A1
20170119409 Ma May 2017 A1
20170143465 Ulm, III May 2017 A1
20170147765 Mehta May 2017 A1
20170150979 John Jun 2017 A1
20170151032 Loisel Jun 2017 A1
20170165062 Rothstein Jun 2017 A1
20170165065 Rothstein et al. Jun 2017 A1
20170165454 Tuohy et al. Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170172772 Khenansho Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170189035 Porter Jul 2017 A1
20170189041 Cox et al. Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224467 Piccagli et al. Aug 2017 A1
20170224511 Dwork et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231749 Perkins et al. Aug 2017 A1
20170252064 Staunton Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281331 Perkins et al. Oct 2017 A1
20170281344 Costello Oct 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170281912 Melder et al. Oct 2017 A1
20170290593 Cruise et al. Oct 2017 A1
20170290654 Sethna Oct 2017 A1
20170296324 Argentine Oct 2017 A1
20170296325 Marrocco et al. Oct 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170304041 Argentine Oct 2017 A1
20170304097 Corwin et al. Oct 2017 A1
20170304595 Nagasrinivasa et al. Oct 2017 A1
20170312109 Le Nov 2017 A1
20170312484 Shipley et al. Nov 2017 A1
20170316561 Helm et al. Nov 2017 A1
20170319826 Bowman et al. Nov 2017 A1
20170333228 Orth et al. Nov 2017 A1
20170333236 Greenan Nov 2017 A1
20170333678 Bowman et al. Nov 2017 A1
20170340383 Bloom et al. Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20180140315 Bowman et al. May 2018 A1
20180206865 Martin et al. Jul 2018 A1
20180207399 Chou et al. Jul 2018 A1
20180263650 Wanami et al. Sep 2018 A1
20180325537 Shamay et al. Nov 2018 A1
20180326024 Prochazka et al. Nov 2018 A1
20180344338 Brady et al. Dec 2018 A1
20190000492 Casey et al. Jan 2019 A1
20190015061 Liebeskind et al. Jan 2019 A1
20190167284 Friedman et al. Jun 2019 A1
20190239907 Brady Aug 2019 A1
20190292273 Hanotin et al. Sep 2019 A1
20190374239 Martin et al. Dec 2019 A1
20190380723 Grandfield et al. Dec 2019 A1
20190388097 Girdhar et al. Dec 2019 A1
20200000483 Brady et al. Jan 2020 A1
20200009150 Chamorro Sanchez Jan 2020 A1
20200085444 Vale et al. Mar 2020 A1
20200100804 Casey et al. Apr 2020 A1
20200297364 Choe et al. Sep 2020 A1
20200390459 Casey Dec 2020 A1
20210005321 Hwang Jan 2021 A1
20210007757 Casey et al. Jan 2021 A1
20210228223 Casey et al. Jul 2021 A1
20220192739 Deen et al. Jun 2022 A1
Foreign Referenced Citations (109)
Number Date Country
2557083 Jun 2003 CN
101172051 May 2008 CN
102307613 Jan 2012 CN
102316809 Jan 2012 CN
102596098 Jul 2012 CN
103764049 Apr 2014 CN
104042304 Sep 2014 CN
105208950 Dec 2015 CN
105662532 Jun 2016 CN
205359559 Jul 2016 CN
107530090 Jan 2018 CN
208582467 Mar 2019 CN
202009001951 Mar 2010 DE
102009056450 Jun 2011 DE
102010010849 Sep 2011 DE
102010014778 Oct 2011 DE
102010024085 Dec 2011 DE
102011014586 Sep 2012 DE
1153581 Nov 2001 EP
2301450 Mar 2011 EP
2438891 Apr 2012 EP
2628455 Aug 2013 EP
3156004 Apr 2017 EP
3593742 Jan 2020 EP
3669802 Jun 2020 EP
3858291 Aug 2021 EP
2210456 Jul 2004 ES
2427554 Jan 2007 GB
2494820 Mar 2013 GB
H0919438 Jan 1997 JP
2014511223 May 2014 JP
2014525796 Oct 2014 JP
2015-505250 Feb 2015 JP
2016-513505 May 2016 JP
2019-526365 Sep 2019 JP
9424926 Nov 1994 WO
9727808 Aug 1997 WO
9738631 Oct 1997 WO
9920335 Apr 1999 WO
9956801 Nov 1999 WO
9960933 Dec 1999 WO
0121077 Mar 2001 WO
0202162 Jan 2002 WO
0211627 Feb 2002 WO
0243616 Jun 2002 WO
02070061 Sep 2002 WO
02094111 Nov 2002 WO
03002006 Jan 2003 WO
03030751 Apr 2003 WO
03051448 Jun 2003 WO
2004028571 Apr 2004 WO
2004056275 Jul 2004 WO
2005000130 Jan 2005 WO
2005027779 Mar 2005 WO
2006021407 Mar 2006 WO
2006031410 Mar 2006 WO
2006107641 Oct 2006 WO
2006135823 Dec 2006 WO
2007054307 May 2007 WO
2007068424 Jun 2007 WO
2008034615 Mar 2008 WO
2008051431 May 2008 WO
2008131116 Oct 2008 WO
2008135823 Nov 2008 WO
2009031338 Mar 2009 WO
2009076482 Jun 2009 WO
2009086482 Jul 2009 WO
2009105710 Aug 2009 WO
2010010545 Jan 2010 WO
2010046897 Apr 2010 WO
2010075565 Jul 2010 WO
2010102307 Sep 2010 WO
2010146581 Dec 2010 WO
2011013556 Feb 2011 WO
2011066961 Jun 2011 WO
2011082319 Jul 2011 WO
2011095352 Aug 2011 WO
2011106426 Sep 2011 WO
2011110316 Sep 2011 WO
2011135556 Nov 2011 WO
2012052982 Apr 2012 WO
2012064726 May 2012 WO
2012081020 Jun 2012 WO
2012110619 Aug 2012 WO
2012120490 Sep 2012 WO
2012156924 Nov 2012 WO
2013016435 Jan 2013 WO
2013072777 May 2013 WO
2013105099 Jul 2013 WO
2013109756 Jul 2013 WO
2013187927 Dec 2013 WO
2014047650 Mar 2014 WO
2014081892 May 2014 WO
2014139845 Sep 2014 WO
2014169266 Oct 2014 WO
2014178198 Nov 2014 WO
2015061365 Apr 2015 WO
2015103547 Jul 2015 WO
2015134625 Sep 2015 WO
2015179324 Nov 2015 WO
2015189354 Dec 2015 WO
2016010995 Jan 2016 WO
2016089451 Jun 2016 WO
2017089424 Jun 2017 WO
WO 2017090473 Jun 2017 WO
WO 2017103686 Jun 2017 WO
WO 2017161204 Sep 2017 WO
WO 2020039082 Feb 2020 WO
WO 2021113302 Jun 2021 WO
Non-Patent Literature Citations (2)
Entry
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn)
Extended European Search Report issued in European Patent Application No. 22 16 2599 dated Aug. 2, 2022.
Related Publications (1)
Number Date Country
20220296262 A1 Sep 2022 US